PT-141 (Bremelanotide)

Research-centric overview

Peptide

### Summary PT-141 (Bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, primarily investigated for its potential to treat sexual dysfunction, particularly in women experiencing hypoactive sexual desire disorder. Its mechanism of action involves the modulation of pathways related to sexual arousal and desire.

Community effect votes, structured logs, and side-effect summaries.

Effect profile (overview)

Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Jun 2, 2026

Studies indexed

Human

Animal

AI analyzed

Evidence mix0% human · 0% animal · 0% cellular · 0% review

Highest phase: Preclinical onlyYears covered: 2025–2026

Librarian pulse — latest actionsFull changelog ↓

Jun 2, 5:00 PMRe-scoredScored effects for PT-141 (Bremelanotide)
Jun 2, 5:00 PMVerifiedVerified content for PT-141 (Bremelanotide): accurate
Jun 1, 6:00 AMRefreshedRefreshed content for PT-141 (Bremelanotide)

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)Clinical TrialClinicalTrials.govPublished Feb 1, 2006Added Apr 16, 2026

This study evaluated the safety and efficacy of Bremelanotide in women diagnosed with Female Sexual Arousal Disorder (FSAD). The specific dose and duration of treatment were not reported in the abstract. The findings indicated some level of efficacy, but no specific numeric outcomes were provided.

Phase: PHASE2Status: COMPLETED

Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)Clinical TrialClinicalTrials.govPublished Jan 1, 2015Added Apr 16, 2026

This study evaluated the efficacy and safety of subcutaneous Bremelanotide in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD). The trial included a randomized, double-blind, placebo-controlled design with an open-label extension phase. Results regarding specific numeric outcomes were not provided in the abstract.

Phase: PHASE3Status: COMPLETED

A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)Clinical TrialClinicalTrials.govPublished Jun 1, 2011Added Apr 16, 2026

This study evaluated the efficacy and safety of subcutaneously administered Bremelanotide in premenopausal women with Female Sexual Arousal Disorder (FSAD) and/or Hypoactive Sexual Desire Disorder (HSDD). The trial was placebo-controlled and randomized. Not reported in abstract.

Phase: PHASE2Status: COMPLETED

Semantic Scholar search for PT-141 (Bremelanotide)StudySemanticScholarAdded Dec 12, 2025

Not reported in abstract.

FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.StudyPubMedAdded Dec 12, 2025

Not reported in abstract.

Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.StudyPubMedAdded Dec 12, 2025

Not reported in abstract.

Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.StudyPubMedAdded Dec 12, 2025

Not reported in abstract.

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.

Librarian Changelog

Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.

1h agoScoring70%

Scored effects for PT-141 (Bremelanotide)

1h agoVerificationai-researcher95%

Verified content for PT-141 (Bremelanotide): accurate

1d agoRefreshai-researcher85%